ANL Adlai Nortye Ltd Market Capitalization to Book Value Ratio

ANL (Adlai Nortye Ltd) - company brandmark

Adlai Nortye Ltd. (ANL) leverages patent protection for its developments to navigate stringent regulatory oversight in the US and China. The company's environmental strategy is based on purifying laboratory emissions and transitioning to green energy. This price chart on the GURU.Markets platform, where the indicator stands at 3.06, reflects the price action of an asset whose resilience remains independent of GDP cycles and seasonal fluctuations.

adlainortye.com (ANL) Capitalization to Book Value Ratio: for the period 02/21/2024 - 10/30/2026
Flagship merchandise of adlainortye.com

Capital stability is critical for Adlai Nortye Ltd. within the biotech sector, where molecule licensing requires massive reserves to secure FDA approval. This indicator compares the business's market value with its net assets. By analyzing the current ratio of the company's value to its book capitalization, an investor determines the extent of market overvaluation or undervaluation of real resources. This chart reflects the business's ability to maintain a premium amidst operational risks, while a decline in the metric signals a potential squeeze on margins.

Who Adlai Nortye Ltd. competes with

ONC: Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio halozyme.com|RVMD (Revolution Medicines, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Ascentage Pharma Group International|Market Value to Book Value Ratio CG Oncology Corp (CGON)|UroGen Pharma Corp - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio BCAX (Bicara Therapeutics Inc.)|PSNL - Market Cap to Net Assets Ratio|Erasca - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Delcath Systems Inc|YmAbs (YMAB) - Market Value to Book Value Ratio|Aura Corp - Market Value to Book Value|Market Cap to Net Assets Ratio CADL|ARAY: Market Value to Book Value|Market Capitalization to Book Value Ratio SLS|Market Cap to Net Assets Ratio Actuate Therapeutics Inc. ACTU|Citius Oncology, Inc - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio TuHURA Biosciences Inc. HURA|TARA - Market Value to Book Value Ratio|Market Value to Book Value FATE (fatetherapeutics.com)|WHWK: Market Capitalization to Book Value Ratio|Market-to-Book Ratio TScan Therapeutics, Inc. (TCRX)|CSBR (Champions Oncology Inc) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio XBiotech USA|Market Capitalization to Book Value Ratio CVM|ostherapies.com - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Radiopharm Theranostics RADX|Artiva Biotherapeutics Inc. - Market Value to Book Value Ratio|Veru Pharma - Market Capitalization to Book Value Ratio|TPST - Market Capitalization to Book Value Ratio|XLO: Market Capitalization to Book Value Ratio|RENB - Market Capitalization to Book Value|Market Cap to Net Assets Ratio MURA|KAPA: Market Value to Book Value|Market Value to Book Value Ratio OnKure Therapeutics Inc (OKUR)|w2.cytomed.sg - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Curis CRIS|Apollomics Inc. (APLM) - Market-to-Book Ratio|THAR - Market Value to Book Value Ratio|Market Value to Book Value ADVB (Advanced Biomed Inc)|GNPX (Genprex, Inc) - Market Cap to Net Assets Ratio|CLDI: Market Cap to Book Value Multiple|Market Cap to Net Assets Ratio SBFM|Market-to-Book Ratio Xenetic Bio XBIO|Market Capitalization to Book Value Ratio SLRX|PPBT - Market-to-Book Ratio|American Oncology Network, Inc. - Market Cap to Net Assets Ratio|Market Value to Book Value BGNE|CKPT - Market Value to Book Value Ratio|ELEV: Market Value to Book Value Ratio|ICAD (icadmed.com) - Market Cap to Net Assets Ratio|IKNA: Market Cap to Book Value Multiple|NTBL (Notable Labs Inc.) - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio VIRX (Viracta)|Market Cap to Net Assets Ratio MOR (MorphoSys AG)|Market Capitalization to Book Value nayabiosciences.com|Market Capitalization to Book Value Ratio AAPGV (Ascentage Pharma)